<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644785</url>
  </required_header>
  <id_info>
    <org_study_id>2014/10</org_study_id>
    <nct_id>NCT02644785</nct_id>
  </id_info>
  <brief_title>Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions</brief_title>
  <official_title>Investigation of Anaphylactic Reaction in Cases Undergoing Cardiac By-Pass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mustafa Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mustafa Kemal University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to assess tryptase test efficacy for measuring the allergic response to
      protamine during cardiac bypass surgery. Additionally, the investigators aim to establish a
      differential diagnosis on the basis of potential allergens or clinical causes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous blood samples from cardiac surgery cases will be obtained for tryptase measurement
      upon admission to the operating room (OR) and immediately prior to and 30 min after protamine
      infusion initiation. A rapid effect-response-based clinical assessment will be made using
      clinical and laboratory monitoring data for diagnosis and treatment decisions during
      protamine infusion, which may complicate the recovery from surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients number with high tryptase level (&gt; 25 µg/L ).</measure>
    <time_frame>30 min</time_frame>
    <description>Tryptase will be measured using the ImmunoCAP Tryptase kit (Phadia, Uppsala, Sweden), and the cutoff level for elevated tryptase is &gt;11.5 µg/L. A 25 µg/L cutoff value has been found to be highly suggestive of an İmmunoglobulin E (IgE) -mediated reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients number with allergic reaction involving of 1 or more organ/systems (skin, respiratory, or cardiovascular system) following the study drug infusion. In this study, mainly the cardiovascular and skin symptoms will be focused on.</measure>
    <time_frame>30 min</time_frame>
    <description>These outcomes will be determined following the Council for International Organizations of Medical Sciences (CIOMS 1999 and ) definitions for anaphylactic reactions. Additionally, (World Health Organization - Uppsala Monitoring Centre) WHO-UMC system will be used for assesment of causality categories for adverse drug reactions.</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Protamine Allergy</condition>
  <condition>Protamine Adverse Reaction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>protamine</intervention_name>
    <description>Protamine infusion exposures</description>
    <other_name>promin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        elective cardiac By-Pass surgery cases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac by-pass cases

        Exclusion Criteria:

          -  Insulin dependent diabetes

          -  Atopy

          -  Drug allergy history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menekse Oksar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mustafa Kemal University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mustafa Kemal University Hospital</name>
      <address>
        <city>Hatay</city>
        <zip>31100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Krishna+MT%2C+York+M%2C+Chin+T%2C+et+al%3A+Multi-centre+retrospective+analysis+of+anaphylaxis+during+general+anaesthesia+in+the+United+Kingdom%3A+aetiology+and+diagnostic+performance+of+acute+serum+tryptase.+Clin+Exp+Immunol+178%3A399-404%2C+2014</url>
    <description>The authors reported that elevated acute serum tryptase (&gt;141% from baseline or absolute tryptase &gt;15.7 mg/L) is highly predictive of IgE-mediated anaphylaxis and that these two methods of interpretation are comparable.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=malinovskyjm,decagnys,wesself,etal.systematicfollow-upincreasesincidenceofanaphylaxisduringadversereactionsinanesthetizedpatientsactaanaesthesiascand52175-181,2008&amp;cmd=correctspelling</url>
    <description>Malinovsky et al. reported that tryptase concentrations were elevated in 50% of their patients, and the positive and negative predictive values (PPV and NPV) of tryptase were 100% for both tryptase &gt;12 and &gt;25 at the first samples.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Mertes+Anesthesiology+2003%3B99%3A536-45</url>
    <description>Krishna et al. reported sensitivities, specificities, PPV and NPV for a tryptase of &gt;25 mcg/L to be 64, 74, 82 and 52 respectively in 103 patients which were similar to the values reported by Mertes et al.</description>
  </link>
  <results_reference>
    <citation>Krishna MT, York M, Chin T, Gnanakumaran G, Heslegrave J, Derbridge C, Huissoon A, Diwakar L, Eren E, Crossman RJ, Khan N, Williams AP. Multi-centre retrospective analysis of anaphylaxis during general anaesthesia in the United Kingdom: aetiology and diagnostic performance of acute serum tryptase. Clin Exp Immunol. 2014 Nov;178(2):399-404. doi: 10.1111/cei.12424.</citation>
    <PMID>25070464</PMID>
  </results_reference>
  <results_reference>
    <citation>Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand. 2008 Feb;52(2):175-81. Epub 2007 Nov 13.</citation>
    <PMID>18005384</PMID>
  </results_reference>
  <results_reference>
    <citation>Mertes PM, Laxenaire MC, Alla F; Groupe d'Etudes des Réactions Anaphylactoïdes Peranesthésiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003 Sep;99(3):536-45.</citation>
    <PMID>12960536</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mustafa Kemal University</investigator_affiliation>
    <investigator_full_name>MENEKSE OKSAR</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cardiac by-pass</keyword>
  <keyword>protamine</keyword>
  <keyword>tryptase</keyword>
  <keyword>hypotension</keyword>
  <keyword>anaphylaxis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

